Luttrell W E, Castle M C
Department of Pharmacology, Eastern Virginia Medical School, Norfolk 23501.
Biochem Pharmacol. 1993 Dec 3;46(11):2083-92. doi: 10.1016/0006-2952(93)90651-c.
Soman (pinacolyl methylphosphonofluoridate), a highly toxic organophosphate compound, has been found to be a strong inhibitor of hepatic microsomal carboxylesterase in vitro, but an enhancer of carboxylesterase when administered in vivo. In response to this paradoxical observation, the objective of this study was to determine if soman could cause true enhancement of the metabolism of drugs in the guinea pig and, if so, to characterize the enhanced enzyme activity. Following the pretreatment of guinea pigs with 90% LD50 soman, enhancement of microsomal esterase activity was noted 12 and 24 hr after pretreatment. Using Michaelis-Menten enzyme kinetic studies, enhancement was found to occur with liver carboxylesterase and procaine esterase, but not with aniline hydroxylase. Since the soman-enzyme complex was known to undergo aging with the release of pinacolyl alcohol and the subsequent formation of pinacolone, the effects of these metabolites on the activity of liver microsomal enzymes in vitro were explored. Pinacolone and pinacolyl alcohol produced enzyme enhancement in vitro in a manner similar to that produced by soman pretreatment. These effects were compared with those made by acetone in the same incubations, since the enhancing influence of acetone has already been well documented. Similarity was found between the in vitro effects of acetone and the effects of pinacolone and pinacolyl alcohol. Lastly, the in vivo effects of pinacolone on the activities of the same liver microsomal enzymes were studied following pretreatment of the guinea pigs with 90% LDLo (lowest published lethal dose) pinacolone. Pretreating guinea pigs with pinacolone prior to killing them enhanced liver microsomal carboxylesterase and procaine esterase activities, but had no effect on microsomal aniline hydroxylase activity. This pattern of enzyme enhancement was similar to that observed after soman pretreatment. Therefore, soman was found to enhance hepatic microsomal esterase activity in the guinea pig in a manner similar to that seen with its metabolites, as well as acetone. This information may give insight into how the efficacy and toxicity of therapeutic drugs, other xenobiotics, and endogenous materials may be altered in individuals who survive an exposure to soman.
梭曼(频那基甲基膦酰氟)是一种剧毒有机磷化合物,已发现它在体外是肝微粒体羧酸酯酶的强抑制剂,但在体内给药时却是羧酸酯酶的增强剂。针对这一矛盾的观察结果,本研究的目的是确定梭曼是否能真正增强豚鼠体内药物的代谢,如果可以,则对增强的酶活性进行表征。用90%半数致死剂量的梭曼预处理豚鼠后,在预处理后12小时和24小时观察到微粒体酯酶活性增强。通过米氏酶动力学研究发现,肝脏羧酸酯酶和普鲁卡因酯酶活性增强,但苯胺羟化酶活性未增强。由于已知梭曼 - 酶复合物会老化,释放出频那醇并随后形成频那酮,因此研究了这些代谢产物对体外肝微粒体酶活性的影响。频那酮和频那醇在体外产生的酶增强作用方式与梭曼预处理产生的相似。在相同孵育条件下将这些作用与丙酮产生的作用进行了比较,因为丙酮的增强作用已经有充分记录。发现丙酮的体外作用与频那酮和频那醇的作用相似。最后,在用90%最低致死剂量的频那酮预处理豚鼠后,研究了频那酮对相同肝微粒体酶活性的体内作用。在处死豚鼠前用频那酮预处理可增强肝脏微粒体羧酸酯酶和普鲁卡因酯酶活性,但对微粒体苯胺羟化酶活性无影响。这种酶增强模式与梭曼预处理后观察到的相似。因此,发现梭曼以与其代谢产物以及丙酮相似的方式增强豚鼠肝脏微粒体酯酶活性。这些信息可能有助于深入了解在接触梭曼后存活的个体中,治疗药物、其他外源性物质和内源性物质的疗效和毒性可能如何改变。